You are here

  • Home
  • Archive
  • Volume 29, Issue Suppl 4
  • TP53 mutations in cell-free DNA as early markers of therapeutic response in platinum-resistant relapsed ovarian cancer (PROC): a prospective translational analysis of the phase II GANNET53 clinical trial

Citation Tools

Article menu
Download PDFPDF
Best Oral Communications/Late-Breaking Abstracts 3 – Ovarian Cancer
TP53 mutations in cell-free DNA as early markers of therapeutic response in platinum-resistant relapsed ovarian cancer (PROC): a prospective translational analysis of the phase II GANNET53 clinical trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Vanderstichele A, Concin N, Busschaert P, et al
TP53 mutations in cell-free DNA as early markers of therapeutic response in platinum-resistant relapsed ovarian cancer (PROC): a prospective translational analysis of the phase II GANNET53 clinical trial
International Journal of Gynecologic Cancer 2019;29:A11.